TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma.

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trabectedin (Primary) ; Doxorubicin
Indications Soft tissue sarcoma
Focus Adverse reactions; Therapeutic Use
Acronyms TRUSTS

Most Recent Events

17 Jun 2019 This trial has been completed in UK - MHRA(End date:2016-04-16) as per European Clinical Trials Database record.
12 Sep 2017 Results of a pooled analysis from EORTC 62012,EORTC62043 EORTC 62072 and EORTC62091 trials presented at the 42nd European Society for Medical Oncology Congress
09 Nov 2016 This trial has been completed in Poland (End date:2016-04-16) as per European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight